Monoclonal antibodies specific for human hematopoietic cell surface glycoproteins

Claim 2

A mouse monoclonal antibody produced by a hybridoma formed by fusion of cells from a mouse myeloma line and either spleen cells or lymph node cells from a mouse previously immunized with human hematopoietic cells, which antibody reacts with specific hematopoietic cell surface glycoproteins that react with monoclonal antibody produced by cell line ATCC CRL 8036, which glycoproteins are present in essentially all human nucleated hematopoietic cells, but said monoclonal antibody does not react with other normal human tissue cells.

Claim 3

The monoclonal antibody of claim 1 which is produced from a hybridoma formed by the fusion of S194/5.XX0.BU.1 myeloma cells and cells from a mouse previously immunized with CCRF-CEM human T leukemic cells.

Claim 6

A method in accordance with claim 3 wherein said hybridoma is injected into athymic nude mice and recovering the antibodies from ascitic fluid therefrom.

Claim 7

A monoclonal antibody which reacts with specific hematopoietic cell surface glycoproteins that react with monoclonal antibody produced by cell line ATCC CRL 8036, which glycoproteins are present in essentially all human nucleated hematopoietic cells, but said antibody does not react with other normal human tissue cells, the monoclonal antibody prepared by the method comprising the steps of: (a) immunizing mice with human hematopoietic cell; (b) removing the spleens from said mice and making a suspension of the spleen cells; (c) fusing said spleen cells with mouse myeloma cells in the presence of a fusion promoter; (d) diluting and separately culturing the fused cells in a medium which will only support growth of fused myeloma cells; (e) examining the medium from each of the separate cultures containing a hybridoma for the presence of antibodies which react with human hematopoietic cells; (f) selecting and cloning a hybridoma producing a monoclonal antibody which reacts with cell surface glycoproteins particular to all human nucleated hematopoietic cells, and specifically with said cell surface glycoproteins, but not with cell surface glycoproteins from other normal tissue cells; and (g) recovering said monoclonal antibody.

Claim 8

A monoclonal antibody which reacts with specific hematopoietic cell surface glycoproteins that react with monoclonal antibody produced by cell line ATCC CRL 8036, which glycoproteins are present in essentially all human nucleated hematopoietic cells, but said antibody does not react with other normal human tissue cells, the monoclonal antibody prepared by the method comprising the steps of: (a) immunizing mice with human hematopoietic cell; (b) removing the spleens from said mice and making a suspension of the spleen cells; (c) fusing said spleen cells with mouse myeloma cells in the presence of a fusion promoter; (d) diluting and separately culturing the fused cells in a medium which will only support growth of fused myeloma cells; (e) examining the medium from each of the separate cultures containing a hybridoma for the presence of antibodies which react with human hematopoietic cells; (f) selecting and cloning a hybridoma producing a monoclonal antibody which reacts with cell surface glycoproteins particular to all human nucleated hematopoietic cells, and specifically with said cell surface glycoproteins, but not with cell surface glycoproteins from other normal tissue cells; and (g) recovering said monoclonal antibody.

Claim 9

The monoclonal antibody of claim 5 which is prepared by injecting said hybridoma clones intraperitoneally into a histocompatible animal and recovering said antibody from ascitic fluid of the animal.

Claim 10

The monoclonal antibody of claim 5 prepared by the method wherein BALB/c mice are immunized with CCRF-CEM normal human T leukemic cells.

Claim 11

The monoclonal antibody of claim 7 prepared by the method wherein said spleen cells are fused with SI94/5.XX0.BU.1 mouse myeloma cells.

Claim 12

The monoclonal antibody according to claim 5 produced by the cell line ATCC CRL 8036.